Multiple Myeloma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +17 more
2022-03-30
Mar 30, 2022
N
Biospecimen Procurement for Genitourinary Malignancies Branch Immunotherapy Protocols
Recruiting
  • Multiple Myeloma
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    N
    Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
    Recruiting
    • Myelodysplastic Syndrome
    • +4 more
    • Rituximab
    • +6 more
    • Bethesda, Maryland
    • +1 more
    2022-04-07
    Apr 7, 2022
    N
    Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    N
    Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
    Enrolling by invitation
    • Lyphoma, B-Cell
    • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-04-07
      Apr 7, 2022
      A
      Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
      Recruiting
      • Multiple Myeloma
      • Lemzoparlimab
      • +4 more
      • Tucson, Arizona
      • +57 more
      2022-04-06
      Apr 6, 2022
      N
      Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
      Not yet recruiting
      • Multiple Myeloma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      N
      A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...
      Recruiting
      • Solid Tumor Malignancy
      • +4 more
      • mRNA-1273
      • Bethesda, Maryland
      • +1 more
      2022-04-07
      Apr 7, 2022
      H
      Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
      Recruiting
      • Multiple Myeloma
      • Daratumumab Injection
      • +3 more
      • Tampa, Florida
        H. Lee Moffitt Cancer & Research Institute
      2022-04-07
      Apr 7, 2022
      N
      Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
      Completed
      • Multiple Myeloma
      • +3 more
        • Iowa City, Iowa
        • +1 more
        2022-04-07
        Apr 7, 2022
        N
        Tissue Collection for Studies of Lymph Cancer
        Recruiting
        • Hodgkin Disease
        • +4 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          2022-04-07
          Apr 7, 2022
          N
          Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
          Completed
          • Leukemia
          • +3 more
            • Bethesda, Maryland
              National Cancer Institute (NCI), 9000 Rockville Pike
            2022-04-07
            Apr 7, 2022
            N
            Agriculture Health Study
            Active, not recruiting
            • Prostate Cancer
            • +3 more
              • Iowa City, Iowa
              • +1 more
              2022-04-07
              Apr 7, 2022
              N
              Natural Killer Cells and Bortezomib to Treat Cancer - 2021
              Completed
              • Chronic Myeloid Leukemia (CML)
              • +4 more
              • Bethesda, Maryland
                National Institutes of Health Clinical Center, 9000 Rockville Pi
              2022-04-07
              Apr 7, 2022
              R
              REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma
              Not yet recruiting
              • Multiple Myeloma
              • (no location specified)
              2022-03-28
              Mar 28, 2022
              U
              Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
              Not yet recruiting
              • Multiple Myeloma
              • Cancer
              • Chapel Hill, North Carolina
              • +2 more
              2022-04-06
              Apr 6, 2022
              S
              Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
              Recruiting
              • Hodgkin Lymphoma
              • +3 more
              • Biostrap arm band
              • Palo Alto, California
                Stanford University
              2022-03-29
              Mar 29, 2022
              P
              Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
              Recruiting
              • Multiple Myeloma
              • Namdong-gu, Incheon-gwangyeoksi [incheon], Korea, Republic of
              • +2 more
              2022-03-30
              Mar 30, 2022
              F
              Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
              Active, not recruiting
              • Multiple Myeloma
              • Torino, Italy
                Division of Hematology, Molinette Hospital
              2022-04-06
              Apr 6, 2022
              T
              A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies
              Recruiting
              • Lymphoma
              • +3 more
              • Los Angeles, California
              • +13 more
              2022-03-28
              Mar 28, 2022
              W
              Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
              Recruiting
              • Multiple Myeloma
              • Saint Louis, Missouri
                Washington University School of Medicine
              2022-04-04
              Apr 4, 2022
              I
              MInimal Residual Disease Adapted Strategy
              Recruiting
              • Multiple Myeloma
              • AMIENS Cedex 1, France
              • +67 more
              2022-03-28
              Mar 28, 2022
              Z
              A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
              Recruiting
              • Multiple Myeloma
              • Hangzhou, Zhejiang, China
                The first affiliated hospital of medical college of zhejiang uni
              2022-04-05
              Apr 5, 2022
              S
              Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
              Active, not recruiting
              • Multiple Myeloma
              • Isatuximab SAR650984
              • Beijing, China
              • +2 more
              2022-04-05
              Apr 5, 2022
              J
              A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
              Recruiting
              • Multiple Myeloma
              • San Francisco, California
              • +43 more
              2022-03-28
              Mar 28, 2022